Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose indacaterol dose-ranging crossover study in moderate to severe COPD
2006-004069-33Phase 2Completed
- Sponsor
- Novartis
- Start
- Sep 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of indacaterol in chronic obstructive pulmonary disease (COPD) (5 arms), sponsored by Novartis. Primary endpoint: 24-hour post-dose trough FEV1. Started Sep 2006; status: completed.
02
Drugs
indacaterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2006-004069-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004069-33.